Canton Strategic Holdings (CNTN) Shares Outstanding (Diluted Average) (2022 - 2026)
Canton Strategic Holdings (CNTN) reported Shares Outstanding (Diluted Average) of $207.7 million for Q1 2026, up 7973.41% on a YoY basis from $2.6 million in Q1 2025, and up 548.08% quarter-over-quarter from $32.0 million in Q4 2025.
Canton Strategic Holdings (CNTN) Shares Outstanding (Diluted Average) (2022 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Shares Outstanding (Diluted Average) for 5 years, with the latest figure at $207.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 7973.41% year-over-year to $207.7 million; the trailing twelve-month figure through Mar 2026 stood at $207.7 million (up 7973.41% YoY), and the FY2025 full-year result was $32.0 million, up 2372.39% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $207.7 million, up from $32.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $207.7 million in Q1 2026, with the low at $44889.0 in Q2 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $17.5 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) plunged 99.61% — and 2026, when it surged 7973.41%.
- Canton Strategic Holdings' Shares Outstanding (Diluted Average) stood at $452686.0 in 2022, then tumbled by 80.76% to $87079.0 in 2023, then soared by 1388.64% to $1.3 million in 2024, then jumped by 2372.39% to $32.0 million in 2025, then soared by 548.08% to $207.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $207.7 million (Q1 2026), $32.0 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 207.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.71 Mn |
| Dec 31, 2025 | 32.05 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 962,149.00 |
| Mar 31, 2024 | 885,683.00 |
| Dec 31, 2023 | 87,079.00 |
| Sep 30, 2023 | 46,169.00 |
| Jun 30, 2023 | 44,889.00 |
| Mar 31, 2023 | 460,580.00 |
| Dec 31, 2022 | 452,686.00 |
| Sep 30, 2022 | 11.53 Mn |
| Jun 30, 2022 | 11.57 Mn |